Holen Sie sich die Stockscreener-App
15.01
3.69%
-0.605
Schlusskurs vom Vortag:
$15.61
Offen:
$15.78
24-Stunden-Volumen:
485.57K
Relative Volume:
0.38
Marktkapitalisierung:
$1.54B
Einnahmen:
$83.98M
Nettoeinkommen (Verlust:
$-264.46M
KGV:
-4.9324
EPS:
-3.0421
Netto-Cashflow:
$-263.47M
1W Leistung:
-0.44%
1M Leistung:
-3.63%
6M Leistung:
+66.31%
1J Leistung:
+13.98%
1-Tages-Spanne:
$14.62
$16.11
1-Wochen-Bereich:
$14.62
$16.18
52-Wochen-Spanne:
$8.18
$22.50
Nurix Therapeutics Inc Stock (NRIX) Company Profile
Firmenname
Nurix Therapeutics Inc
Sektor
Branche
Telefon
(415) 660-5320
Adresse
1600 SIERRA POINT PKWY, BRISBANE
Compare NRIX vs VRTX, REGN, ARGX, ALNY, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
NRIX
Nurix Therapeutics Inc
|
15.01 | 1.61B | 83.98M | -264.46M | -263.47M | -3.0421 |
|
VRTX
Vertex Pharmaceuticals Inc
|
469.98 | 121.46B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
743.73 | 78.93B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
700.42 | 43.87B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
313.47 | 42.07B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
283.88 | 31.65B | 5.36B | 287.73M | 924.18M | 2.5229 |
Nurix Therapeutics Inc Stock (NRIX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-01-08 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2025-11-24 | Fortgesetzt | Truist | Buy |
| 2025-10-21 | Eingeleitet | Mizuho | Outperform |
| 2025-03-17 | Eingeleitet | Leerink Partners | Market Perform |
| 2024-12-10 | Eingeleitet | BTIG Research | Buy |
| 2024-12-06 | Eingeleitet | BMO Capital Markets | Outperform |
| 2024-10-24 | Eingeleitet | UBS | Buy |
| 2024-10-11 | Eingeleitet | Jefferies | Buy |
| 2024-09-06 | Fortgesetzt | Robert W. Baird | Outperform |
| 2024-07-31 | Eingeleitet | Truist | Buy |
| 2023-06-26 | Fortgesetzt | Oppenheimer | Outperform |
| 2023-03-09 | Eingeleitet | Barclays | Overweight |
| 2023-02-28 | Eingeleitet | Oppenheimer | Outperform |
| 2022-10-11 | Eingeleitet | Morgan Stanley | Equal-Weight |
| 2022-05-31 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2022-02-10 | Eingeleitet | Wells Fargo | Equal Weight |
| 2021-12-29 | Eingeleitet | H.C. Wainwright | Buy |
| 2021-10-14 | Eingeleitet | SVB Leerink | Outperform |
| 2021-06-04 | Fortgesetzt | Robert W. Baird | Outperform |
| 2021-04-30 | Fortgesetzt | Piper Sandler | Overweight |
| 2021-04-30 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2021-04-14 | Eingeleitet | Berenberg | Buy |
| 2020-11-19 | Eingeleitet | Robert W. Baird | Outperform |
| 2020-08-18 | Eingeleitet | JP Morgan | Overweight |
| 2020-08-18 | Eingeleitet | Needham | Buy |
| 2020-08-18 | Eingeleitet | Piper Sandler | Overweight |
| 2020-08-18 | Eingeleitet | Stifel | Buy |
Alle ansehen
Nurix Therapeutics Inc Aktie (NRIX) Neueste Nachrichten
Gains Report: Should I buy Nurix Therapeutics Inc stock now2026 Short Interest & Precise Swing Trade Entry Alerts - baoquankhu1.vn
Nurix Stock Is Down 6% This Past Year, but One Biotech Fund Still Boosted Its Bet By $63 Million - AOL.com
Nurix Therapeutics, Inc. (NASDAQ:NRIX) Receives Average Rating of "Moderate Buy" from Analysts - MarketBeat
Surprises Report: Can Oak Woods Acquisition Corporation Equity Right disrupt its industry2026 Snapshot & Pattern Based Trade Signal System - baoquankhu1.vn
Understanding Momentum Shifts in (NRIX) - Stock Traders Daily
Market Moves: Will Nurix Therapeutics Inc announce a stock splitPortfolio Value Summary & Verified Technical Trade Signals - baoquankhu1.vn
Rhenman & Partners Asset Management AB Purchases 162,500 Shares of Nurix Therapeutics, Inc. $NRIX - MarketBeat
Does Nurix Therapeutics' (NRIX) Expanded ATM Capacity Reframe Its Balance Between Funding Flexibility and Dilution? - Sahm
Can Nurix Therapeutics Inc scale operations efficiently2025 Earnings Impact & Stepwise Trade Signal Guides - baoquankhu1.vn
Is Nurix Therapeutics Inc. stock a top momentum playJuly 2025 Levels & Scalable Portfolio Growth Ideas - Naître et grandir
Nurix Therapeutics amends equity distribution agreement for $413.65 million stock offering - Investing.com
Nurix Therapeutics Expands ATM Equity Offering Capacity - TipRanks
Nurix Therapeutics adds $413.65M at-the-market equity facility with Piper Sandler - TradingView
Inflation Data: Whats the RSI of Nurix Therapeutics Inc stockPortfolio Value Report & Safe Investment Capital Preservation Plans - baoquankhu1.vn
ARK Investment Management LLC Has $13.96 Million Position in Nurix Therapeutics, Inc. $NRIX - MarketBeat
Nurix Therapeutics, Inc. $NRIX Stock Position Increased by Amova Asset Management Americas Inc. - MarketBeat
Handelsbanken Fonder AB Buys 240,000 Shares of Nurix Therapeutics, Inc. $NRIX - MarketBeat
Insider Sell: Christine Ring Sells Shares of Nurix Therapeutics Inc (NRIX) - GuruFocus
Planned stock sale by Nurix (NRIX) chief legal officer disclosed - Stock Titan
Christine Ring sells RSU shares (NRIX) under 10b5-1 plan via Morgan Stanley - Stock Titan
Buybacks Report: What are Calix Incs growth levers2025 Bull vs Bear & AI Based Trade Execution Alerts - baoquankhu1.vn
Nurix Therapeutics (NRIX) Valuation Check After Recent Share Price Volatility And Rich Price To Sales Multiple - Yahoo Finance
NRIX Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Avoiding Lag: Real-Time Signals in (NRIX) Movement - Stock Traders Daily
NRIX PE Ratio & Valuation, Is NRIX Overvalued - Intellectia AI
Redmile Group Increases Nurix Therapeutics Stake by 4.4M Shares - Intellectia AI
Nurix Stock Is Down 6% This Past Year, but One Biotech Fund Still Boosted Its Bet By $63 Million - The Motley Fool
Nurix Therapeutics, Inc. (NRIX) Stock Analysis: Is There a 90% Upside Potential on the Horizon? - DirectorsTalk Interviews
Baker Bros discloses 7.2% Nurix (NRIX) ownership stake - Stock Titan
NRIX Technical Analysis & ETF Price Forecast - Intellectia AI
Discipline and Rules-Based Execution in NRIX Response - Stock Traders Daily
Nurix Therapeutics, Inc. (NASDAQ:NRIX) Receives Consensus Rating of "Moderate Buy" from Brokerages - MarketBeat
Nurix Therapeutics Highlights STAT6, BTK and IRAK4 Degraders as Immunology Pipeline Gains Spotlight - MarketBeat
Does Nurix Therapeutics Inc. have a sustainable dividendJuly 2025 Institutional & Entry Point Confirmation Signals - mfd.ru
Is Nurix Therapeutics Inc. undervalued by DCF analysisQuarterly Portfolio Report & Accurate Entry/Exit Alerts - mfd.ru
What is the long term forecast for Nurix Therapeutics Inc. stockEarnings Summary Report & Reliable Trade Execution Plans - mfd.ru
Nurix Therapeutics, Inc. (NRIX) Stock Analysis: Emerging Potential With 90% Upside - DirectorsTalk Interviews
NRIX: Degrader therapies advance in immunology, with key milestones expected for STAT6 and BTK programs - TradingView
Why Nurix Therapeutics Inc. stock remains resilient2025 Earnings Impact & Daily Technical Stock Forecast Reports - mfd.ru
Nurix (NASDAQ: NRIX) CFO awarded 93,750 options and 42,875 RSUs - Stock Titan
Ring Christine, chief legal officer at Nurix, sells $237k in NRIX stock - Investing.com Canada
Assessing Nurix Therapeutics (NRIX) Valuation After Revenue Growth Wider Loss And New Shelf Registration - simplywall.st
HC Wainwright remains a buy on Nurix Therapeutics (NRIX) - MSN
Nurix Therapeutics (NRIX) Is Down 7.4% After Pivotal Bexobrutideg Update and Wider 2025 Loss - Sahm
VIX Spike: Can Nurix Therapeutics Inc sustain its profitabilityGDP Growth & Weekly High Return Stock Forecasts - baoquankhu1.vn
Nurix Therapeutics (NRIX) Is Down 7.4% After Wider 2025 Losses And New ESOP Share ShelfWhat's Changed - Yahoo Finance
Stifel raised Nurix Therapeutics, Inc. (NRIX) price target to $35 and maintains buy ahead of 2026 catalysts - MSN
Nurix Therapeutics advances study for NX-5948 in CLL and SLL patients - MSN
Behavioral Patterns of NRIX and Institutional Flows - Stock Traders Daily
Is Nurix Therapeutics Inc forming a bullish divergenceWeekly Trend Report & Free Risk Controlled Daily Trade Plans - baoquankhu1.vn
Nurix Therapeutics, Inc. (NRIX): A Bull Case Theory - Finviz
Finanzdaten der Nurix Therapeutics Inc-Aktie (NRIX)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.18%
0.28%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):